deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04404660

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia

Sponsor: Autolus Limited

Conditions Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Interventions AUTO1
Updated 22 times since 2020 Last updated: Sep 8, 2025 Started: Jun 3, 2020 Primary completion: Jun 30, 2029 Completion: Jun 30, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia and is currently ongoing. Autolus Limited leads this study, which shows 22 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Nov 2021 · 6 months · monthly snapshot~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Jul 2023 · 10 months · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 11 months · monthly snapshot

Change History

22 versions recorded

  1. Oct 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Oct 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 17 earlier versions

  1. Sep 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jul 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2022 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  7. Nov 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  8. May 2021 — Nov 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  12. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  13. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  14. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

  15. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  16. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  17. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Autolus Limited
Data source: Autolus Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Barcelona, Spain , Birmingham, United Kingdom , Boston, United States , Bristol, United Kingdom , Cambridge, United Kingdom , Chicago, United States , Cleveland, United States , Dallas, United States and 22 more locations